Sirtuin Inhibitor

OSS_128167 (Standard) is the analytical standard of OSS_128167 (HY-107454). This product is intended for research and analytical applications. OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects.

Nicotinamide-d₃ (Niacinamide-d₃) is deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.

SIRT2-IN-18 (Compound 8) is a SIRT2 inhibitor with IC₅₀s of 5.3  and 12.3 μM for SmSIRT2 and hSIRT2, respectively. SIRT2-IN-18 shows potent antischistosomal activities against both Liberian and Puerto Rican strains of Schistosoma mansoni and reduces schistosomula and adult worm pair viability, pairing, and egg production, with low cytotoxicity in mammalian cells. SIRT2-IN-18 increases histone H3 hyperacetylation and induces cytochrome c-mediated apoptosis.

JGB1741 (Standard) is the analytical standard of JGB1741 (HY-111329). This product is intended for research and analytical applications. JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC₅₀ of ～15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC₅₀>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research.

A1B11 is a selective SIRT inhibitor (SIRT2:IC50=5.3 μM) that can be used in the study of neurodegenerative diseases.

ZINC08790006 is a high-affinity SIRT1 inhibitor, and it can be used in the research of SIRT1-related diseases (such as aging, diabetes and cancer).

2-(2-Thienyl) benzofuran is a SIRT1 inhibitor with an inhibition rate of up to 63.6%. 2-(2-Thienyl) benzofuran inhibits the proliferation of breast cancer cells, and its antiproliferative activity is comparable to that of Suramin (HY-B0879). 2-(2-Thienyl) benzofuran can be used in breast cancer-related research.

AGK2 (Standard) is the analytical standard of AGK2 (HY-100578). This product is intended for research and analytical applications. AGK2 is a selective SIRT2 inhibitor with an IC50 of 3.5 μM. AGK2 inhibits SIRT1 and SIRT3 with IC50s of 30 and 91 μM, respectively.

Dihydrocoumarin (Standard) is the analytical standard of Dihydrocoumarin. This product is intended for research and analytical applications. Dihydrocoumarin is a compound found in Melilotus officinalis. Dihydrocoumarin is a yeast Sir2p inhibitor. Dihydrocoumarin also inhibits human SIRT1 and SIRT2 with IC50s of 208 μM and 295 μM, respectively.

6,7-Dimethoxy-1,3-bis (4-methoxyphenyl) isoquinoline is a SIRT1 inhibitor with a K_D value of 0.5 μM.

2"-O-Galloylhyperin (Standard) is the analytical standard of 2"-O-Galloylhyperin (HY-N0526). This product is intended for research and analytical applications. 2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease.

JFD00244 (Standard) is the analytical standard of JFD00244 (HY-108986). This product is intended for research and analytical applications. JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2.